Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis

Shahrear, Sazzad; Islam, Abul B.M.M.K.

doi:10.1007/s11030-022-10515-4

Cited by 6 publications

(7 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, multiple human clinical trials have begun, indicating that mRNA vaccines are now considered to be a safe and effective alternative to subunit protein, chimeric virus and even DNA-based therapies in the form of vaccination [ 32 ]. One of the benefits of mRNA-based vaccines is their ability to induce the transient expression and accumulation of selected antigens in the cytoplasm, which then triggers an immune response against the target pathogen [ 33 ]. This approach may offer several advantages over traditional vaccine strategies, including ease of production, rapid development and improved efficacy.…”

Section: Discussionmentioning

confidence: 99%

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Asadinezhad,

Khoshnood,

Asadollahi

et al. 2023

Briefings in Bioinformatics

View full text Add to dashboard Cite

The rising issue of antibiotic resistance has made treating Pseudomonas aeruginosa infections increasingly challenging. Therefore, vaccines have emerged as a viable alternative to antibiotics for preventing P. aeruginosa infections in susceptible individuals. With its superior accuracy, high efficiency in stimulating cellular and humoral immune responses, and low cost, mRNA vaccine technology is quickly replacing traditional methods. This study aimed to design a novel mRNA vaccine by using in silico approaches against P. aeruginosa. The research team identified five surface and antigenic proteins and selected their appropriate epitopes with immunoinformatic tools. These epitopes were then examined for toxicity, allergenicity and homology. The researchers also checked their presentation and identification by major histocompatibility complex cells and other immune cells through valuable tools like molecular docking. They subsequently modeled a multi-epitope protein and optimized it. The mRNA was analyzed in terms of structure and stability, after which the immune system’s response against the new vaccine was simulated. The results indicated that the designed mRNA construct could be an effective and promising vaccine that requires laboratory and clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Asadinezhad,

Khoshnood,

Asadollahi

et al. 2023

Briefings in Bioinformatics

View full text Add to dashboard Cite

show abstract

Section: Challenges and Prospects In The Research Of Novel Tb Vaccinesmentioning

confidence: 99%

“…In 2022, a study proposed a hypothetical mRNA vaccine MT.P495, which targets the phosphate-binding protein PstS1 of mycobacterium tuberculosis [ 318 ]. This study used several bioinformatics tools targeting the phosphate-binding protein PstS1 of MTB and has also been computationally tested for its ability to elicit an immunogenic response and safety, predicting several types of T cell and B cell epitopes present within this antigen and their ability to generate an immune response within the host body [ 318 ]. PstS1 protein is an immunodominant, TLR-2 agonist, inorganic phosphate up-taking lipoprotein found on the cell membrane surface of MTB as well as exhibits function as an adhesion molecule that facilitates binding with a macrophage through mannose receptor (MR).…”

Section: Challenges and Prospects In The Research Of Novel Tb Vaccinesmentioning

confidence: 99%

“…All of the results above suggest that the proposed mRNA vaccine candidate, MT.P495, will probably elicit a strong immune response, specifically against MTB. In order to develop a viable MTB vaccine in the future, this modeled mRNA is an excellent vaccine model that can be readily employed for laboratory testing, including in vitro as well as in vivo studies [ 318 ].…”

Section: Challenges and Prospects In The Research Of Novel Tb Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Next-Generation TB Vaccines: Progress, Challenges, and Prospects

Zhuang,

Ye,

et al. 2023

Vaccines

View full text Add to dashboard Cite

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a prevalent global infectious disease and a leading cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette–Guérin (BCG). However, BCG demonstrates limited efficacy, particularly in adults. Efforts to develop effective TB vaccines have been ongoing for nearly a century. In this review, we have examined the current obstacles in TB vaccine research and emphasized the significance of understanding the interaction mechanism between MTB and hosts in order to provide new avenues for research and establish a solid foundation for the development of novel vaccines. We have also assessed various TB vaccine candidates, including inactivated vaccines, attenuated live vaccines, subunit vaccines, viral vector vaccines, DNA vaccines, and the emerging mRNA vaccines as well as virus-like particle (VLP)-based vaccines, which are currently in preclinical stages or clinical trials. Furthermore, we have discussed the challenges and opportunities associated with developing different types of TB vaccines and outlined future directions for TB vaccine research, aiming to expedite the development of effective vaccines. This comprehensive review offers a summary of the progress made in the field of novel TB vaccines.

show abstract

“…Immunopeptidomics, based on mass spectrometry identification of MHC-bound peptides from infected cells, has been demonstrated as a useful approach for the identification of novel antigenic peptides for vaccine development ( 140 ). Furthermore, Immunoinformatic approaches provide useful tools for in silico modelling of mRNA vaccines against TB, combining epitope identification, mRNA construction and optimisation and immune simulation to guide further in vivo evaluation ( 141 – 143 ).…”

Section: Interest Of Mrna Vaccine Technology For Tb Hiv and Malariamentioning

confidence: 99%

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Matarazzo

Bettencourt

2023

Front. Immunol.

View full text Add to dashboard Cite

The success of the first licensed mRNA-based vaccines against COVID-19 has created a widespread interest on mRNA technology for vaccinology. As expected, the number of mRNA vaccines in preclinical and clinical development increased exponentially since 2020, including numerous improvements in mRNA formulation design, delivery methods and manufacturing processes. However, the technology faces challenges such as the cost of raw materials, the lack of standardization, and delivery optimization. MRNA technology may provide a solution to some of the emerging infectious diseases as well as the deadliest hard-to-treat infectious diseases malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), for which an effective vaccine, easily deployable to endemic areas is urgently needed. In this review, we discuss the functional structure, design, manufacturing processes and delivery methods of mRNA vaccines. We provide an up-to-date overview of the preclinical and clinical development of mRNA vaccines against infectious diseases, and discuss the immunogenicity, efficacy and correlates of protection of mRNA vaccines, with particular focus on research and development of mRNA vaccines against malaria, tuberculosis and HIV.

show abstract

Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis

Cited by 6 publications

References 127 publications

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Development of innovative multi-epitope mRNA vaccine against Pseudomonas aeruginosa using in silico approaches

Next-Generation TB Vaccines: Progress, Challenges, and Prospects

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV

Contact Info

Product

Resources

About